MedTrace Logo

Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea

NCT04646902 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2023-12-07

No results posted yet for this study

Summary

Obstructive Sleep Apnea (OSA) is an independent risk factor for hypertension (HTN) and the most common cause of resistant HTN. The mechanisms underlying OSA-associated HTN are not completely understood. This is crucial to find novel therapeutic targets of OSA-associated HTN. The Aryl Hydrocarbon Receptor (AHR) is a cytosolic transcription factor that has been linked with the pathogenesis of HTN.

This study aims to evaluate the role of endogenous ligands of AHR such as kynurenine in discriminating patients with OSA-associated HTN. For that aim, a case-control study will be performed in patients with and without hypertension exposed and not exposed to OSA. Kynurenine and other metabolites will be quantified in urine and serum samples.

Conditions

  • Hypertension Secondary

Sponsors & Collaborators

  • Centro Hospitalar Lisboa Ocidental

    collaborator OTHER_GOV

  • Centro Hospitalar de Lisboa Central

    collaborator OTHER

  • Hospital Beatriz Ângelo

    collaborator OTHER

  • Hospital Fernando Fonseca

    collaborator UNKNOWN

  • Hospital da Luz, Portugal

    collaborator OTHER

  • Universidade Nova de Lisboa

    lead OTHER

Principal Investigators

  • Maria E Monteiro, PhD · Universidade NOVA Lisboa

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-25
Primary Completion
2023-09-01
Completion
2024-03-01

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04646902 on ClinicalTrials.gov